Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease

Chrishan S Samuel, Hasangika Bodaragama, Jackie Chew, Robert E Widdop, Simon G Royce, Tim D Hewitson

Research output: Contribution to journalArticleResearchpeer-review

47 Citations (Scopus)

Abstract

Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation (fibrosis) in diverse pathogeneses. However, its efficacy relative to renin-angiotensin system blockade, the most effective antifibrotic strategy currently available, is not known. We compared the individual versus combined antifibrotic effects of serelaxin (a recombinant form of human gene-2 relaxin) and the angiotensin-converting enzyme inhibitor enalapril, in preventative (started before injury) and therapeutic (treatment of established fibrosis) strategies, in a mouse model of isoprenaline-induced cardiac injury (at 17 days). Changes in systolic blood pressure, organ hypertrophy, and tissue remodeling/fibrosis were assessed. Pretreatment with serelaxin (0.5 mg/kg per day via subcutaneous administration) alone reduced cardiac fibrosis to a greater extent than enalapril (200 mg/L via drinking water; equivalent to 48 mg/kg per day) alone (P
Original languageEnglish
Pages (from-to)315 - 322
Number of pages8
JournalHypertension
Volume64
Issue number2
DOIs
Publication statusPublished - 2014

Cite this

@article{927c89835c9e49b2aa52ae125a8ddde7,
title = "Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease",
abstract = "Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation (fibrosis) in diverse pathogeneses. However, its efficacy relative to renin-angiotensin system blockade, the most effective antifibrotic strategy currently available, is not known. We compared the individual versus combined antifibrotic effects of serelaxin (a recombinant form of human gene-2 relaxin) and the angiotensin-converting enzyme inhibitor enalapril, in preventative (started before injury) and therapeutic (treatment of established fibrosis) strategies, in a mouse model of isoprenaline-induced cardiac injury (at 17 days). Changes in systolic blood pressure, organ hypertrophy, and tissue remodeling/fibrosis were assessed. Pretreatment with serelaxin (0.5 mg/kg per day via subcutaneous administration) alone reduced cardiac fibrosis to a greater extent than enalapril (200 mg/L via drinking water; equivalent to 48 mg/kg per day) alone (P",
author = "Samuel, {Chrishan S} and Hasangika Bodaragama and Jackie Chew and Widdop, {Robert E} and Royce, {Simon G} and Hewitson, {Tim D}",
year = "2014",
doi = "10.1161/HYPERTENSIONAHA.114.03594",
language = "English",
volume = "64",
pages = "315 -- 322",
journal = "Hypertension",
issn = "0194-911X",
publisher = "American Heart Association",
number = "2",

}

Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. / Samuel, Chrishan S; Bodaragama, Hasangika; Chew, Jackie; Widdop, Robert E; Royce, Simon G; Hewitson, Tim D.

In: Hypertension, Vol. 64, No. 2, 2014, p. 315 - 322.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease

AU - Samuel, Chrishan S

AU - Bodaragama, Hasangika

AU - Chew, Jackie

AU - Widdop, Robert E

AU - Royce, Simon G

AU - Hewitson, Tim D

PY - 2014

Y1 - 2014

N2 - Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation (fibrosis) in diverse pathogeneses. However, its efficacy relative to renin-angiotensin system blockade, the most effective antifibrotic strategy currently available, is not known. We compared the individual versus combined antifibrotic effects of serelaxin (a recombinant form of human gene-2 relaxin) and the angiotensin-converting enzyme inhibitor enalapril, in preventative (started before injury) and therapeutic (treatment of established fibrosis) strategies, in a mouse model of isoprenaline-induced cardiac injury (at 17 days). Changes in systolic blood pressure, organ hypertrophy, and tissue remodeling/fibrosis were assessed. Pretreatment with serelaxin (0.5 mg/kg per day via subcutaneous administration) alone reduced cardiac fibrosis to a greater extent than enalapril (200 mg/L via drinking water; equivalent to 48 mg/kg per day) alone (P

AB - Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation (fibrosis) in diverse pathogeneses. However, its efficacy relative to renin-angiotensin system blockade, the most effective antifibrotic strategy currently available, is not known. We compared the individual versus combined antifibrotic effects of serelaxin (a recombinant form of human gene-2 relaxin) and the angiotensin-converting enzyme inhibitor enalapril, in preventative (started before injury) and therapeutic (treatment of established fibrosis) strategies, in a mouse model of isoprenaline-induced cardiac injury (at 17 days). Changes in systolic blood pressure, organ hypertrophy, and tissue remodeling/fibrosis were assessed. Pretreatment with serelaxin (0.5 mg/kg per day via subcutaneous administration) alone reduced cardiac fibrosis to a greater extent than enalapril (200 mg/L via drinking water; equivalent to 48 mg/kg per day) alone (P

UR - http://hyper.ahajournals.org/content/64/2/315.full.pdf+html

U2 - 10.1161/HYPERTENSIONAHA.114.03594

DO - 10.1161/HYPERTENSIONAHA.114.03594

M3 - Article

VL - 64

SP - 315

EP - 322

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -